Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.
Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Takaoka Y, et al. Among authors: namikawa m. Hepatol Res. 2021 Jan;51(1):51-61. doi: 10.1111/hepr.13576. Epub 2020 Oct 20. Hepatol Res. 2021. PMID: 33021009
Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: namikawa m. Hepatol Res. 2020 Mar;50(3):303-312. doi: 10.1111/hepr.13462. Epub 2019 Dec 19. Hepatol Res. 2020. PMID: 31750974
Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study.
Suzuki Y, Naganuma A, Hoshino T, Hatanaka T, Ueno T, Namikawa M, Takizawa D, Arai H, Suzuki H, Takagi H, Tojima H, Yamazaki Y, Sato K, Kakizaki S, Uraoka T. Suzuki Y, et al. Among authors: namikawa m. Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):57-63. doi: 10.51821/84.1.357. Acta Gastroenterol Belg. 2021. PMID: 33639694 Free article.
Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015.
Yamazaki Y, Naganuma A, Arai Y, Takeuchi S, Kobayashi T, Takakusagi S, Hatanaka T, Hoshino T, Namikawa M, Hashizume H, Takizawa D, Ohyama T, Suzuki H, Horiguchi N, Takagi H, Sato K, Kakizaki S, Kusano M, Nagashima S, Takahashi M, Okamoto H, Yamada M. Yamazaki Y, et al. Among authors: namikawa m. Hepatol Res. 2017 Apr;47(5):435-445. doi: 10.1111/hepr.12765. Epub 2016 Jul 27. Hepatol Res. 2017. PMID: 27322051
Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study.
Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Tojima H, Shimada Y, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: namikawa m. Hepatol Res. 2020 Mar;50(3):382-395. doi: 10.1111/hepr.13460. Epub 2019 Dec 10. Hepatol Res. 2020. PMID: 31760660
Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment.
Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: namikawa m. Cancers (Basel). 2020 Oct 10;12(10):2906. doi: 10.3390/cancers12102906. Cancers (Basel). 2020. PMID: 33050527 Free PMC article.
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T, Naganuma A, Shibasaki M, Kohga T, Arai Y, Nagashima T, Ueno T, Namikawa M, Saito S, Hoshino T, Takizawa D, Arai H, Makita F, Kakizaki S, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: namikawa m. Oncology. 2021;99(4):203-214. doi: 10.1159/000511734. Epub 2020 Dec 4. Oncology. 2021. PMID: 33279908
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: namikawa m. Intern Med. 2021;60(19):3061-3070. doi: 10.2169/internalmedicine.6591-20. Epub 2021 Oct 1. Intern Med. 2021. PMID: 34602520 Free PMC article.
59 results